Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by RTW Investments LP

RTW Investments LP reduced its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 5.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,236,549 shares of the company's stock after selling 175,937 shares during the period. Tarsus Pharmaceuticals accounts for about 2.7% of RTW Investments LP's holdings, making the stock its 14th biggest holding. RTW Investments LP owned approximately 8.47% of Tarsus Pharmaceuticals worth $179,208,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Jennison Associates LLC grew its holdings in shares of Tarsus Pharmaceuticals by 14.8% during the 4th quarter. Jennison Associates LLC now owns 2,500,132 shares of the company's stock worth $138,432,000 after purchasing an additional 321,552 shares during the period. Barclays PLC lifted its position in Tarsus Pharmaceuticals by 345.9% in the third quarter. Barclays PLC now owns 98,663 shares of the company's stock valued at $3,246,000 after buying an additional 76,538 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in Tarsus Pharmaceuticals by 0.5% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,146,812 shares of the company's stock worth $63,499,000 after buying an additional 5,565 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter valued at about $1,107,000. Finally, Northern Trust Corp increased its position in shares of Tarsus Pharmaceuticals by 12.6% during the fourth quarter. Northern Trust Corp now owns 357,616 shares of the company's stock valued at $19,801,000 after acquiring an additional 40,061 shares during the last quarter. 90.01% of the stock is owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Stock Down 3.6%

TARS stock traded down $1.63 during midday trading on Wednesday, hitting $43.25. The company's stock had a trading volume of 128,077 shares, compared to its average volume of 697,199. The firm has a 50-day simple moving average of $47.98 and a 200-day simple moving average of $49.19. The firm has a market capitalization of $1.82 billion, a P/E ratio of -11.45 and a beta of 0.94. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals, Inc. has a 52-week low of $20.08 and a 52-week high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The business had revenue of $78.34 million for the quarter, compared to analysts' expectations of $72.50 million. As a group, equities analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on TARS. Barclays decreased their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Jefferies Financial Group upped their price target on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. HC Wainwright reaffirmed a "buy" rating and issued a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a report on Wednesday, January 22nd. Finally, The Goldman Sachs Group raised their target price on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a report on Monday, May 5th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Tarsus Pharmaceuticals currently has an average rating of "Buy" and a consensus price target of $66.33.

Insider Buying and Selling at Tarsus Pharmaceuticals

In related news, insider Dianne C. Whitfield sold 2,315 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $107,161.35. Following the sale, the insider now directly owns 50,751 shares in the company, valued at approximately $2,349,263.79. This represents a 4.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bobak R. Azamian sold 6,000 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $50.00, for a total transaction of $300,000.00. Following the completion of the transaction, the chief executive officer now owns 824,106 shares of the company's stock, valued at $41,205,300. This represents a 0.72% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,542 shares of company stock valued at $1,581,173 in the last quarter. Corporate insiders own 8.25% of the company's stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.